The study utilized a single-blind, randomized, placebo-controlled, crossover design, combined with functional magnetic resonance imaging (fMRI), to analyze the performance of 54 participants (30 with normal insulin sensitivity and 24 with impaired insulin sensitivity) on sensory associative learning tasks while receiving liraglutide and placebo treatments
While possible, maintaining results after stopping GLP-1 therapy is challenging and requires intensive lifestyle modifications including 200-300 minutes of weekly exercise, consistent dietary changes, regular self-monitoring, and often ongoing behavioral support
Obesity is a major risk factor for many chronic conditions like type 2 diabetes and cardiovascular diseases
Renal monitoring is crucial, especially if you experience dehydration from side effects like vomiting or diarrhea
Other oral are in FDA review and could hit the market in 2024
Muscle loss